Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-guided cetuximab modulation with FOLFIRI in RAS-mutated metastatic colorectal cancer
2019-003714-14Phase 2Completed
- Sponsor
- TheraOp gGmbH
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by TheraOp gGmbH. Primary endpoint: Progression-free survival. Started Dec 2019; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2019-003714-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003714-14.